Small molecule-based therapy for p53-deficient tumors: IAPP (Amylin) increases the expression of tumor suppressor PTEN and induces regression of p53-mutated human tumors via up regulation of its target gene, 13/May/2015, 23.17

Adding more years into your life with MicroRNAs: MiRNA-224 decreases aging-related decline in muscle function and enhances the longevity of mammals via down regulation of myostatin, 13/May/2015, 19.02
May 13, 2015
Natural product-based therapy for T2DM: Thermostable extract of fenugreek seeds (TEFS) enhances insulin secretion by increasing glucagon-like peptide-1 secretion via up regulation of its target gene, 13/May/2015, 23.22
May 13, 2015
Show all

A recent study from the Department of Molecular and Cellular Oncology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA [2] Department of Translational Molecular Pathology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA [3] Graduate School of Biomedical Sciences, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA [4] Metastasis Research Center, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA shows that“IAPP-driven metabolic reprogramming induces regression of p53-deficient tumours in vivo.” This study was published in the 29 January  2015 issue of the Journal “Nature” (the no.1 journal in Science with an impact factor of 42) by Prof. Flores ER, Venkatanarayan A and others.

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that:  Small molecule-based therapy for p53-deficient tumors: IAPP (Amylin) increases the expression of tumor suppressor PTEN and induces regression of p53-mutated human tumors via up regulation of its target gene 

Significance:  

Although IAPP has been shown to induce regression of p53-deficient tumours in vivo, the mechanistic basis of which remains unclear.  This study suggests, for the first time, that IAPP (Amylin), by increasing the expression of its target gene, it may increase the expression of tumor suppressor PTEN. Thereby, it may induce regression of p53-mutated human tumors. Thus, pharmacological formulations encompassing IAPP or its analogues  can be used to inhibit the progression of p53-deficient human tumors.

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Web: http://genomediscovery.org

CitationBoominathan,  Small molecule-based therapy for p53-deficient tumors: IAPP (Amylin) increases the expression of tumor suppressor PTEN and induces regression of p53-mutated human tumors via up regulation of its target gene, 13/May/2015, 23.17, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Web: http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

Undisclosed information: How IAPP (Amylin) increases the expression of PTEN

* Research cooperation

Comments are closed.